← Back to Calendar

Rhythm Pharmaceuticals Q1 2026 Earnings

Rhythm Pharmaceuticals · $RYTM
Standard Review Earnings
Catalyst Date
May 8, 2026
Time Remaining
25 days
Review Type
Standard (10 mo)

Live Company Data NGM

Updated just now · Data: FMP
Current Price
$84.39 +45.93%
+$26.56 today
Day: $82.96 – $86.19
Market Cap
N/A
Shares out: 68.29M
Float: 55.45M
52-Week Range
$55.31
$122.20
Current price is at 43% of 52-week range
Avg Volume
838K
Beta
2.14
vs. S&P 500
Sector
Healthcare
Biotechnology
⚠️ Financial data is for informational purposes only. Not investment advice. Prices may be delayed.
Track $RYTM catalysts → get weekly FDA alerts Subscribe Free on Substack →

Indication

Q1 2026 earnings + acquired HO commercial launch update

Key Notes

Q1 2026 earnings expected ~May 2026. IMCIVREE acquired HO PDUFA March 20, 2026 — if approved, Q1 earnings will include early launch data. EMA CHMP opinion expected Q2 2026. EMANATE Phase 3 topline data expected early 2026.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.

Discussion

Share your analysis, research, or questions about this catalyst. No account required.

Rate limit: 5/hr per email
Loading comments...
← Back to Full Calendar